CAP empiric abx

Question 1

Outpatient management

1. for previously healthy patients w no risk factors for MRSA or psuedomonas:
   a. ________
   b. __________
   c. _________

Answer 1

amoxicillin
doxycycline
macrolide

Question 2

outpatient management

2. for patients w comorbid medical conditions such as chronic heart, lung liver, or kidney disease; diabetes; alcoholism; malignancy; asplenia; immunosuppressant conditions or use of immunosuppressive drugs; or use of antibiotics within previous 3 months
   a. _______ or _______ plus an oral beta lactam (___________, __________,_________)
   b. ______ with an oral __________

Answer 2

macrolide, doxycycline
amoxicillin-cavulanate, cefopodoxime, cefuroxime
monotherapy
fluoroquinolone

Question 3

inpatient management of non severe pneumonia (typically not requiring intensive care)

a. a respiratory _________
b. ________ plus a ________. for IV therapy: _________/sulbactam; cefotaxime, ceftriaxone, ceftaroline

For patients with prior respiratory isolation of. MRSA, consider adding coverage for MRSA: ________ or __________

For patients with prior respiratory isolation of psuedomonas aeruginosa, strongly consider adding coverage for P aeurginosa. ___ therapy only !!! : ______________, cefepime, imipenem, meropenem

Answer 3

fluoroquinolone
macrolide, beta lactam
ampicillin
vancomycin, linezolid
IV
piperacillin-tazobactam

Question 4

Inpatient management of severe pneumonia (typically requiring intensive care) all agents are administed __, except as noted

1. ______________ or a respiratory ________ plus IV anti-pneumococcal _______
2. for patients allergic to beta lactam antibiotics a __________ plus _______
3. for patients at risk for p. aueruginosa add coverage for p aeruginosa: ______________, cefepime, imipenem, meropenem, or aztreonam

Answer 4

azithromycin
fluoroquinolone
beta lactam
fluoroquinolone, aztreonam
piperacillin-tazobactam

Question 5

Inpatient management of severe pneumonia (typically requiring intensive care) all agents are administed __, except as noted

4. for patients at risk for psuedonomas infection AND who are critically ill, at incresed risk for drug resistance, or if local incidence of monotherapy resistant Pseudomonas is >10% consider adding either
   a. an anti pseudomonal _________ (_____ or _______)
   OR
   b. an ___________ (gentamicin, tobramycin)

for pts at risk for MRSA add coverage for MRSA: ______ or ______

Answer 5

IV 
fluoroqinolone
cipro or levofloxcacin
aminoglicosyde
vancomycin, linezolid